drugset / Trial / NCT06685796
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).
Timeline
- Start
- 2023-04-12
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEBT-209 | Unknown | 150 mg | Oral |
| Subject | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |